These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34940846)

  • 61. The Impact of
    Cuthbertson DJ; Barriuso J; Lamarca A; Manoharan P; Westwood T; Jaffa M; Fenwick SW; Nuttall C; Lalloo F; Prachalias A; Pizanias M; Wieshmann H; McNamara MG; Hubner R; Srirajaskanthan R; Vivian G; Ramage J; Weickert MO; Pritchard DM; Vinjamuri S; Valle J; Yip VS
    Front Endocrinol (Lausanne); 2021; 12():654975. PubMed ID: 34163434
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
    Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
    Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.
    Werner RA; Weich A; Higuchi T; Schmid JS; Schirbel A; Lassmann M; Wild V; Rudelius M; Kudlich T; Herrmann K; Scheurlen M; Buck AK; Kropf S; Wester HJ; Lapa C
    Theranostics; 2017; 7(6):1489-1498. PubMed ID: 28529632
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy.
    Lütgendorf-Caucig C; Pelak M; Flechl B; Georg P; Fossati P; Stock M; Traub-Weidinger T; Marosi C; Haberler C; Zechmeister-Machhart G; Hermsmeyer L; Hug E; Staudenherz A
    Strahlenther Onkol; 2023 Apr; 199(4):396-403. PubMed ID: 36260109
    [TBL] [Abstract][Full Text] [Related]  

  • 67.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sensitivity Comparison of
    Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
    J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
    [TBL] [Abstract][Full Text] [Related]  

  • 69. F-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography Has High Diagnostic Value for Pelvic and Distant Staging in Patients with High-risk Penile Carcinoma.
    Ottenhof SR; Djajadiningrat RS; Versleijen MWJ; Donswijk ML; van der Noort V; Brouwer OR; Graafland NM; Vegt E; Horenblas S
    Eur Urol Focus; 2022 Jan; 8(1):98-104. PubMed ID: 33685842
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Somatostatin receptor imaging with [
    Zhao L; Pang Y; Wang Y; Chen J; Zhuang Y; Zhang J; Zhao L; Sun L; Wu H; Chen X; Lin Q; Chen H
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1360-1373. PubMed ID: 34665275
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diagnostic values of
    Kumar R; Vankadari K; Mittal BR; Bansal D; Trehan A; Sahu JK; Sankhyan N
    Eur Radiol; 2021 Jul; 31(7):4587-4594. PubMed ID: 33409780
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 3P's of Wermer/MEN1 Syndrome on 68Ga-DOTANOC PET/CT Scan.
    Tripathy S; Prakash S; Arun Raj ST; Kumar A; Shamim SA
    Clin Nucl Med; 2020 Dec; 45(12):e516-e517. PubMed ID: 32796241
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
    Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
    Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D; Mikołajczak R; Kamiński G
    Nucl Med Rev Cent East Eur; 2016; 19(2):88-92. PubMed ID: 27479886
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers.
    Weich A; Higuchi T; Bundschuh RA; Lapa C; Serfling SE; Rowe SP; Pomper MG; Herrmann K; Buck AK; Derlin T; Werner RA
    Mol Imaging Biol; 2022 Aug; 24(4):631-640. PubMed ID: 35233654
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
    Zalom ML; Waxman AD; Yu R; Lee J; Ih G; Wolin EM
    Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 78. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.
    Werner RA; Derlin T; Rowe SP; Bundschuh L; Sheikh GT; Pomper MG; Schulz S; Higuchi T; Buck AK; Bengel FM; Bundschuh RA; Lapa C
    J Nucl Med; 2021 Apr; 62(4):514-520. PubMed ID: 32859702
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs.
    Grawe F; Rosenberger N; Ingenerf M; Beyer L; Eschbach R; Todica A; Seidensticker R; Schmid-Tannwald C; Cyran CC; Ricke J; Bartenstein P; Auernhammer CJ; Ruebenthaler J; Fabritius MP
    Cancer Imaging; 2023 Apr; 23(1):41. PubMed ID: 37098632
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
    Werner RA; Lapa C; Ilhan H; Higuchi T; Buck AK; Lehner S; Bartenstein P; Bengel F; Schatka I; Muegge DO; Papp L; Zsótér N; Große-Ophoff T; Essler M; Bundschuh RA
    Oncotarget; 2017 Jan; 8(4):7039-7049. PubMed ID: 27705948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.